Navigation Links
Study holds promise for new way to fight HIV

There has always been a quest regarding the treatment of AIDS/HIV infection that has been haunting the world. Despite the initiation of a global research, AIDS still remains a puzzle to be tackled effectively. Approximately five percent of patients with HIV, or human immunodeficiency virus, do not develop AIDS, or do so very slowly.//

Past research suggested that such patients maintain higher levels of an enzyme in white blood cells called APOBEC-3G (A3G), and the new study confirmed it in the first experiments on human cells. These patients remain healthy even after years of infection with HIV despite receiving no treatment. These results have confirmed the presence of an innate defense system present in such subjects.

It is believed that A3G "edits," or introduces changes in, the HIV genetic code every time the virus copies itself. By doing so, A3G corrupts the HIV gene code and prevents the virus from reproducing. However, the HIV virus overcomes this difficulty with the help of viral infectivity factor (Vif) that directs the body to destroy A3G. HIV is then free to overwhelm the immune system, leaving patients vulnerable to AIDS infections.

It has been hypothesized that people suffering from the effects of HIV infection do not make or produce sufficient amounts of the A3G protein to combat Vif and shut it down. Therefore protecting whatever amount of A3G that people do have from Vif represents a new way to attack HIV.

To confirm that A3G offers strong protection against HIV, researchers in the current study measured A3G levels in the immune cells of six people not infected with HIV and in 25 patients with the virus. It was found that higher levels of A3G closely corresponded to lower HIV viral levels.

Furthermore, the team determined that nonprogressors have the most A3G editing enzyme, followed by those not infected with HIV and lastly by those progressing toward full-blown AIDS.

The study has t
'"/>




Page: 1 2

Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study holds promise for new way fight HIV

(Date:7/25/2008)... reduces lung function, increases asthma risk, stu...hDay News) -- A clean, fresh-smelling home may act...pe of cleaning and air freshening products you use...leaning products or air fresheners that contain a ... dicholorobenzene (1,4 DCB), can reduce lung funct...
(Date:7/25/2008)... -- BeaconEquity.com announces the,availability of...tors can view all of the daily trading notes for f...ay,s Trade Alerts include: DUSA Pharmaceuticals In...nc. (Nasdaq: MBRK ), NovaMed Inc. (Nasdaq:,NOVA),...asdaq: AFFX ) and,Abaxis Inc. (Nasdaq: ABAX )., ...
(Date:7/25/2008)...rketing Exclusivity Begins -, CORONA, Calif., Jul...als, Inc. (NYSE: WPI ), a leading specialty pharm...iary has commenced commercial,shipment of its Omep... 40mg,strength from its Davie, Florida manufacturi...n has 180 days of marketing exclusivity for being ...
(Date:7/25/2008).../ -- The Elekta Family of Companies will,showcase ... the 2008,American Association of Physicists in Me...e joint forces of Elekta, IMPAC and CMS are delive...elivery solutions that,streamline the treatment pr...as well as enhance clinician efficiency., "Our re...
Breaking Medicine News(10 mins):Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3
...Mayfield Dairy Farms announced today that it is vo... Turtle Tracks ice cream with a code date of 4/11...initiated because the affected product contains pe...abel. No other Mayfield Dairy Farms products are i...
...A combination of molecular-targeted therapy and ho...esearch for those seeking an effective treatment ...he International Journal of Gynecological Cancer. ...med the role of hormone therapy in recurrent ovari...
...South Africa is increasing its efforts to prevent ...g appropriate treatments available in the public ...th training, Minister of Social Development Zola S...Tuesday, BuaNews reports. In addition, Skweyiya s...
...Shri E.Ahmed, Minister of State in the Ministry of...hat the Government has decided to introduce e-pass...st these passports will be issued for diplomats ...the end of 2007. Based on the experience gained fr...
Other Medicine News:Health News:South Africa Increasing Efforts To Contain Drug-Resistant TB, Minister Says 2
(Date:7/23/2008)...ound Pharmaceuticals (SPI) has filed,an Investigat...inical,testing of a proprietary formulation of ebs...aring loss or ototoxicity. The oral capsule,contai... stage lung cancer,and head and neck cancer patien...ks the second development program for SPI to enter...
(Date:7/23/2008)...Call/ -- Dendreon Corporation,(Nasdaq: DNDN ) tod...Monitoring Committee (IDMC) to review in October 2...ing to the Company,s Phase 3 IMPACT (IMmunotherapy... as D9902B) clinical trial,of PROVENGE(R) (sipuleu...active cellular immunotherapy for the treatment of...
(Date:7/22/2008)...evelopment Initiative bring MJFF,s,current active ...ry 20,2009, NEW YORK, July 22 /PRNewswire-USNews...of transformative treatments and a cure for Parkin...arkinson,s Research has awarded,$2.7 million in to...ards,were granted under MJFF,s Therapeutics Develo...
(Date:7/22/2008)...Importance to Patients of Passing a ..., Va., July 22 /- Insmed In...ogics and biopharmaceuticals, today,announced that...t at a,Congressional briefing on Friday, July 25th...shing an approval pathway for follow-on,biologics ...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3Survey Finds U S Healthcare Facilities Not Doing Enough to Curb MRSA 1044 1Survey Finds U S Healthcare Facilities Not Doing Enough to Curb MRSA 1044 2Survey Finds U S Healthcare Facilities Not Doing Enough to Curb MRSA 1044 3EntreMed Announces FDA Acceptance of IND Application for Panzem 28R 29 in Rheumatoid Arthritis 8090 1EntreMed Announces FDA Acceptance of IND Application for Panzem 28R 29 in Rheumatoid Arthritis 8090 2EntreMed Announces FDA Acceptance of IND Application for Panzem 28R 29 in Rheumatoid Arthritis 8090 3EntreMed Announces FDA Acceptance of IND Application for Panzem 28R 29 in Rheumatoid Arthritis 8090 4Rand study examines the effect of policy on entrepreneurship and small businesses 8089 1Rand study examines the effect of policy on entrepreneurship and small businesses 8089 2Ames Laboratory researchers solve fuel cell membrane structure conundrum 2140 1Ames Laboratory researchers solve fuel cell membrane structure conundrum 2140 2
...Genentech and FDA notified,healthcare professional...acheoesophageal (TE) fistula formation in a recent...ll cell lung,cancer (SCLC). This multicenter, non-...dy combined chemotherapy and radiation plus,Avasti...vents of TE,fistula (one fatal) reported in the fi...
...mence shortly, CARMIEL, Israel, April 18, 2007 /PR...Inc. today announced that it has received,written ...stration,(FDA) that it may initiate a Phase III cl...uct candidate, prGCD, a proprietary plant,cell exp...e (GCD),for the treatment of Gaucher Disease, a l...
Other Medicine Technology:Protalix BioTherapeutics, Inc. Receives Approval from the FDA to,Initiate a Phase III Clinical Trial of prGCD 2Protalix BioTherapeutics, Inc. Receives Approval from the FDA to,Initiate a Phase III Clinical Trial of prGCD 3
...t reading of entire racks. Its scanner-based image...s in approximately 10 seconds per rack. Decoded tu...of ActiveX controls is provided to allow for integ...HP Scanner and software. Compatible with Windows 2...
Sealed laminate workbench top with powder-coated steel legs. Height is adjustable from 25"-34". Available in hundreds of sizes and configurations. Accessories include shelves, drawers, light fixtures
Round, height-adjustable, steel laboratory stools with small footprint for small spaces • Choose options like different height-adjustment mechanism or paint finish. • your choice of color
...cal safety labs (BSL) and pharmaceutical applicati...nd easy sterilization. Panels are precision-joined...wipe down and disinfect. One-inch radius corners s...creates strong, rigid surface without external bra...
Medicine Products: